| scholarly article | Q13442814 |
| P2093 | author name string | Patrick L Garcia | |
| Karina J Yoon | |||
| Aubrey L Miller | |||
| P2860 | cites work | Selective inhibition of BET bromodomains | Q24301009 |
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| Histone acetyltransferases: challenges in targeting bi-substrate enzymes | Q26745642 | ||
| Deciphering the role of hedgehog signaling in pancreatic cancer | Q26747103 | ||
| The interplay of histone modifications - writers that read | Q26782196 | ||
| A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas | Q27853017 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Immune checkpoint therapy for pancreatic cancer | Q28078390 | ||
| Targeting the DNA Damage Response in Cancer | Q28082178 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models | Q28212532 | ||
| Targeting bromodomains: epigenetic readers of lysine acetylation | Q28238635 | ||
| The mechanisms behind the therapeutic activity of BET bromodomain inhibition | Q28241504 | ||
| Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer | Q28245071 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| Histone acetylation in gene regulation | Q28254963 | ||
| BET bromodomain inhibition of MYC-amplified medulloblastoma. | Q39050679 | ||
| Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 | ||
| Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies | Q39390859 | ||
| Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP–Mediated Expression of HMGA2 | Q39621410 | ||
| Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells | Q39896274 | ||
| In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas | Q40124759 | ||
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer | Q40187997 | ||
| Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. | Q40386572 | ||
| ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 | ||
| Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model | Q40979902 | ||
| WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner | Q41063971 | ||
| MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX) | Q41471129 | ||
| The promise of epigenomic therapeutics in pancreatic cancer | Q41473804 | ||
| PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. | Q41526004 | ||
| P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer | Q41816428 | ||
| BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen | Q42128109 | ||
| Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells | Q42165194 | ||
| The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. | Q42701804 | ||
| KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer | Q47563012 | ||
| The diverse functions of the PD1 inhibitory pathway | Q47678849 | ||
| A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma | Q50041860 | ||
| Cetuximab for treating non-small cell lung cancer. | Q52657680 | ||
| Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer | Q53040486 | ||
| Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. | Q53649002 | ||
| Pancreatic Cancer | Q54135367 | ||
| The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. | Q54976514 | ||
| Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options | Q56890107 | ||
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation | Q57107580 | ||
| Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer | Q57463795 | ||
| Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN) | Q57782435 | ||
| Immune checkpoint inhibitors: recent progress and potential biomarkers | Q60302456 | ||
| Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? | Q60915341 | ||
| Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors | Q64103640 | ||
| The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors | Q64386855 | ||
| Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study | Q70937645 | ||
| Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas | Q73555144 | ||
| Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells | Q74624551 | ||
| Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression | Q77554681 | ||
| Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis | Q78962304 | ||
| Underutilization of surgical resection in patients with localized pancreatic cancer | Q80713643 | ||
| Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors | Q84002220 | ||
| Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX | Q87058753 | ||
| MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model | Q88953412 | ||
| Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis | Q90438918 | ||
| Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply | Q90611992 | ||
| Cancer statistics, 2019 | Q90941571 | ||
| Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial | Q91986107 | ||
| Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling | Q92483499 | ||
| Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer | Q92523349 | ||
| Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors | Q92946134 | ||
| Tobacco and the risk of pancreatic cancer: a review and meta-analysis | Q28264581 | ||
| The concept of synthetic lethality in the context of anticancer therapy | Q28268061 | ||
| Checkpoint kinase 1 in DNA damage response and cell cycle regulation | Q28287480 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 | ||
| Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions | Q29617672 | ||
| Functions of site-specific histone acetylation and deacetylation | Q29617894 | ||
| Protein prenylation: molecular mechanisms and functional consequences | Q29618038 | ||
| Hedgehog: functions and mechanisms | Q29619190 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| PARP inhibition: PARP1 and beyond | Q29619617 | ||
| Histone acetyltransferase complexes: one size doesn't fit all | Q29620006 | ||
| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer | Q33360410 | ||
| Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study | Q33371000 | ||
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 | ||
| Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. | Q33390876 | ||
| Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. | Q33419897 | ||
| Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis | Q33430378 | ||
| Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer | Q33431711 | ||
| A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. | Q33439342 | ||
| Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 | Q34049250 | ||
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). | Q34049260 | ||
| Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection | Q34093790 | ||
| Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies | Q34293555 | ||
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial | Q34632818 | ||
| Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance | Q34646423 | ||
| Notch signaling, gamma-secretase inhibitors, and cancer therapy | Q34653560 | ||
| Familial pancreatic cancer: genetic advances | Q34658718 | ||
| Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression | Q34734222 | ||
| Protein prenylation: enzymes, therapeutics, and biotechnology applications | Q34992469 | ||
| Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer | Q35659511 | ||
| Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial | Q35828693 | ||
| Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer | Q35830110 | ||
| MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts | Q35839058 | ||
| A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer | Q36206894 | ||
| Development of farnesyl transferase inhibitors: a review | Q36263983 | ||
| The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy | Q36289912 | ||
| Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair | Q36309585 | ||
| A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma | Q36437111 | ||
| Patched, the receptor of Hedgehog, is a lipoprotein receptor | Q36458834 | ||
| Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. | Q36525188 | ||
| Bevacizumab for glioblastoma: current indications, surgical implications, and future directions | Q36822207 | ||
| Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. | Q36881446 | ||
| nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer | Q36901035 | ||
| Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation | Q36922674 | ||
| Epigenetics and epigenetic alterations in pancreatic cancer. | Q37041763 | ||
| Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776 | Q37100166 | ||
| Role of bevacizumab in colorectal cancer growth and its adverse effects: A review | Q37102447 | ||
| Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma | Q37123636 | ||
| Epidermal growth factor receptor in pancreatic cancer. | Q37132640 | ||
| BRCA1 and BRCA2: different roles in a common pathway of genome protection | Q37149848 | ||
| The molecular biology of pancreatic cancer | Q37153303 | ||
| A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair | Q37203855 | ||
| Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma | Q37238675 | ||
| Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment | Q37754925 | ||
| Development of curcumin as an epigenetic agent | Q37769504 | ||
| Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases | Q37883025 | ||
| U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma | Q38091618 | ||
| Notch signaling in pancreatic cancer: oncogene or tumor suppressor? | Q38094850 | ||
| DNA damage sensing by the ATM and ATR kinases. | Q38134064 | ||
| Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling | Q38275751 | ||
| Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. | Q38684978 | ||
| Synthetic lethality and cancer. | Q38709651 | ||
| Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. | Q38784706 | ||
| The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). | Q38847670 | ||
| Targeting WEE1 Kinase in Cancer | Q38900156 | ||
| HDACs and HDAC Inhibitors in Cancer Development and Therapy | Q38947405 | ||
| Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial | Q38994795 | ||
| FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma | Q39028395 | ||
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 104740 | |
| P577 | publication date | 2020-03-02 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Pharmacological Research | Q15724622 |
| P1476 | title | Developing effective combination therapy for pancreatic cancer: An overview | |
| P478 | volume | 155 |
Search more.